Alphamab Oncology (HKG:9966)
Hong Kong · Delayed Price · Currency is HKD 7.28
-0.03 (-0.41%)
Jul 9, 2026, 4:08 PM HKT
Alphamab Oncology Market Cap
Alphamab Oncology has a market cap or net worth of 7.05 billion as of July 9, 2026. Its market cap has decreased by -6.29% in one year.
Market Cap
7.05B
Enterprise Value
5.68B
Revenue
630.11M
Ranking
n/a
PE Ratio
n/a
Stock Price
7.28
Market Cap Chart
Since December 12, 2019, Alphamab Oncology's market cap has decreased from 12.11B to 7.05B, a decrease of -41.78%. That is a compound annual growth rate of -7.89%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jul 9, 2026 | 7.05B | -25.72% |
| Dec 31, 2025 | 9.49B | 181.80% |
| Dec 31, 2024 | 3.37B | -47.42% |
| Dec 29, 2023 | 6.41B | -36.87% |
| Dec 30, 2022 | 10.15B | -20.36% |
| Dec 31, 2021 | 12.74B | -16.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 12, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| HBM Holdings | 9.92B |
| Everest Medicines | 9.62B |
| CARsgen Therapeutics Holdings | 9.10B |
| Suzhou Ribo Life Science | 8.85B |
| CStone Pharmaceuticals | 8.55B |
| Abbisko Cayman | 8.13B |
| LongBio Pharma (Suzhou) | 8.02B |
| Lepu Biopharma | 7.76B |